Synthetic agonist/antagonist opioid analgesic, approved Dec. 29 and licensed by Wyeht-Ayerst to Astra, will be not be a scheduled drug. Earlier this year, FDA's Drug Abuse Advisory Committee recommended that dezocine be placed in Schedule V of the Controlled Substances Act based on the drug's abuse potential ("The Pink Sheet" Aug. 14, p. 4). Of the four other agonist/antagonist analgesics to reach the U.S., two have been scheduled: Sterling's Talwin and Norwich-Eaton's Buprenex. Dalgan's approval letter states that the company has agreed to "perform a postmarketing surveillance study to assess the incidence of abuse during the first three years of marketing.
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.